The Atrial Fibrillation-Market Insights & Drugs Sales Forecast (AF) -2020 report provides an overview of the disease, epidemiology and global market trends for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. According to DelveInsight, Global Atrial Fibrillation market was $7.2 billion in 2015 and expected to grow to $12.5 billion by 2020 with and compound annual growth rate (CAGR) of 11.62%.
Coagulation is an important phenomenon of body to stop external bleeding but when clots are formed in blood vessels, it can be lethal. Blood clots in arteries can lead to heart attack and when formed in the blood vessels of brain can lead to stroke. Thus, anticoagulants are used to prevent the formation of blood clots in the body. Anticoagulants are proved to be a beneficial medication for the treatment of Atrial fibrillation, Deep Vein Thrombosis, Pulmonary Embolism and Stroke.
Key Coverage and Benefits:
• The report will help in developing business strategies by understanding the trends shaping and driving the global Atrial Fibrillation (AF) market.
• Identifying patient populations in the global Atrial Fibrillation (AF) market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the best opportunities for Atrial Fibrillation (AF) therapeutics in each of the markets covered.
• To understand the future market competition in the global Atrial Fibrillation (AF) therapeutics market and Insightful review of the key market drivers and barriers.
Scope of the Report:
• Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management and current treatment options.
• Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
• The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2015-2020.
• It also provides Atrial fibrillation (AF) for United States, EU5 and Japan from 2015 and forecasted Market to 2020.
'
Executive Summary
Market Share of Anticoagulants in 2015 and 2020
Worldwide Market Share of Anticoagulants in 2015
Worldwide Market Share of Anticoagulants in 2020
Chapter 1 Anticoagulants Introduction
Warfarin
Low Molecular Weight Heparins
New Oral Anticoagulants (NOAC)
Chapter 2 Atrial Fibrillation
Disease Overview
Epidemiology of Atrial Fibrillation
Treatment Landscape
Treatment Algorithm
Treatment Goals
Treatment Details
Chapter 3 Key Marketed Anticoagulants
Novel Oral Anticoagulants Comparison
Reversal Agents (Antidotes)
Chapter 4 Anticoagulants Market Assessment by AF
Key Findings
Global Anticoagulants Market Sales by Atrial Fibrillation (AF)
Global Anticoagulants Market Share (%) in Atrial Fibrillation
Chapter 5 United States Anticoagulants Market Assessment by AF
Key Findings
United States Anticoagulants Market Sales by Atrial Fibrillation
United States Anticoagulants Market Share (%) in Atrial Fibrillation
Chapter 6 Europe 5 Anticoagulants Market Assessment by AF
Key Findings
Europe 5 Anticoagulants Market Sales by Atrial Fibrillation
Europe 5 Anticoagulants Market Share (%) in Atrial Fibrillation
Chapter 7 Japan Anticoagulants Market Assessment by AF
Key Findings
Japan Anticoagulants Market Sales by Atrial Fibrillation
Japan Anticoagulants Market Share (%) in Atrial Fibrillation
Chapter 8 Xarelto (rivaroxaban) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy of Xarelto
Safety of Xarelto
Side effects of Drugs
Cost of Therapy
Global Drug Sales
Xarelto Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Xarelto Historical Sales and Forecasted Sales (2011-2020) by AF
Clinical Trials Information
SWOT Analysis of Xarelto
Chapter 9 Pradaxa (dabigatran etexilate mesylate) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy of Pradaxa
Safety of Pradaxa
Side effects of Drugs
Cost of Therapy
Global Drug Sales
Pradaxa Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Pradaxa Historical Sales and Forecasted Sales (2011-2020) by AF
Clinical Trial Information
SWOT Analysis of Pradaxa
Chapter 10 Eliquis(Apixaban) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy and Safety of Eliquis
Side effects of Eliquis
Cost of Therapy
Global Drug Sales
Eliquis Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Eliquis Historical Sales and Forecasted Sales (2011-2020) by AF
Clinical Trial Information
SWOT Analysis of Eliquis
Chapter 11 Savaysa (edoxaban tosylate) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy of Savaysa
Safety of Savaysa
Side Effects of Savaysa
Cost of Therapy
Global Drug Sales
Savaysa Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Savaysa Historical Sales and Forecasted Sales (2011-2020) by AF
Clinical Trial Information
SWOT Analysis of Savaysa
Chapter 12 Market Drivers and Constraints
Factors Driving the Market Growth
Factors Constraining the Market Growth
Consulting Services
Disclaimer
About DelveInsight
Tables
Table 1 Key Marketed Anticoagulants
Table 2 Comparison of NOACs & Warfarin
Table 3 Global Anticoagulants Sales in Atrial Fibrillation 2011-2020 (USD MM)
Table 4 Global Anticoagulants Sales in Atrial Fibrillation – 2015-2020 (USD MM)
Table 5 US Anticoagulants Sales in Atrial Fibrillation 2011-2020 (USD MM)
Table 6 US Anticoagulants Sales in Atrial Fibrillation - 2015-2020 (USD MM)
Table 7 EU5 Anticoagulants Sales in Atrial Fibrillation 2011-2020 (USD MM)
Table 8 EU5 Anticoagulants Sales in Atrial Fibrillation - 2015-2020 (USD MM)
Table 9 Japan Anticoagulants Sales in Atrial Fibrillation 2011-2020 (USD MM)
Table 10 Japan Anticoagulants Sales in Atrial Fibrillation - 2015-2020 (USD MM)
Table 11 Xarelto Historical Sales and Forecasted Sales (2011-2020)(USD MM)
Table 12 Xarelto Sales by Atrial Fibrillation (AF) (USD MM)
Table 13 Xarelto, Clinical Trials by Zone, 2016
Table 14 Pradaxa Historical Sales and Forecasted Sales (2011-2020)(USD MM)
Table 15Pradaxa Sales by Atrial Fibrillation (AF) (USD MM)
Table 16 Pradaxa, Clinical Trials by Zone, 2016
Table 17 Eliquis Historical Sales and Forecasted Sales (2011-2020)(USD MM)
Table 18Eliquis Sales by Atrial Fibrillation (AF) (USD MM)
Table 19 Eliquis, Clinical Trials by Zone, 2016
Table 20Savaysa Historical Sales and Forecasted Sales (2011-2020)(USD MM)
Table 21SavaysaSales by Atrial Fibrillation (AF) (USD MM)
Table 22 Savaysa, Clinical Trials by Zone, 2016
Figures
Figure 1 Global Anticoagulants Sales in Atrial Fibrillation- 2011-2020
Figure 2 Global Anticoagulants Market Share (%) in Atrial Fibrillation - 2011-2020
Figure 3 US Anticoagulants Sales in Atrial Fibrillation- 2011-2020
Figure 4 US Anticoagulants Market Share (%) in Atrial Fibrillation - 2011-2020
Figure 5 EU5 Anticoagulants Sales in Atrial Fibrillation- 2011-2020
Figure 6 EU5 Anticoagulants Market Share (%) in Atrial Fibrillation - 2011-2020
Figure 7 Japan Anticoagulants Sales in Atrial Fibrillation- 2011-2020
Figure 8 Japan Anticoagulants Market Share (%) in Atrial Fibrillation - 2011-2020
Figure 9 Xarelto Historical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 10 Xarelto Sales by Atrial Fibrillation (AF)(USD MM)
Figure 11 Xarelto, Clinical Trials by Zone (%), 2016
Figure 12 Pradaxa Historical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 13 PradaxaSales by Atrial Fibrillation (AF)(USD MM)
Figure 14 Pradaxa, Clinical Trials by Zone (%), 2016
Figure 15 Eliquis Historical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 16 EliquisSales by Atrial Fibrillation (AF)(USD MM)
Figure 17 Eliquis, Clinical Trials by Zone (%), 2016
Figure 18 SavaysaHistorical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 19 SavaysaSales by Atrial Fibrillation (AF)(USD MM)
Figure 20 Savaysa, Clinical Trials by Zone (%), 2016
Bayer
Janssen Pharmaceutica
Boehringer Ingelheim
Bristol-Myers Squib
Daiichi Sankyo
